Spyre Therapeutics
Open
$80.92
Prev. Close
$80.89
High
$80.95
Low
$80.72
Market Snapshot
$6.35B
-35.4
-3.16
112
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Spyre Therapeutics successfully completed enrollment for its SKYWAY Phase 2 trial, marking a significant milestone in advancing its therapeutic development initiatives.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Recently from Cashu
Spyre Therapeutics Advances Research on Rheumatic Diseases and Expands Drug Licensing Opportunities
Spyre Therapeutics (Ticker: SYRE) announces significant progress in its clinical research efforts focused on rheumatic diseases. SKYWAY Phase 2 Trial Enrollment Complete The company has successfully c…
Spyre Therapeutics Expands SPY003 Licensing Agreement, Enhances Opportunities Across Health Conditions
Spyre Therapeutics (Ticker: SYRE) announces a pivotal expansion of its licensing agreement with Paragon Therapeutics, a move that significantly broadens the scope of its investigational drug, SPY003.…
Spyre Therapeutics Completes Enrollment for Phase 2 Trial of SPY072 Ahead of Schedule
Spyre Therapeutics announces a significant milestone in its Phase 2 SKYWAY trial, successfully completing enrollment for the rheumatoid arthritis cohort ahead of schedule. This progression presents an…
Spyre Therapeutics Strengthens Position Amid Economic Uncertainty in Biotech Sector
Spyre Therapeutics Navigates an Uncertain Economic Landscape in Biotech Sector In the wake of recent market volatility, Spyre Therapeutics focuses on strengthening its position within the biotechnolog…